

European Biopharmaceutical Enterprises (EBE) is the European trade association that represents biopharmaceutical companies of all sizes operating in Europe. EBE was established in 2000 as a specialised group of EFPIA and is headquartered in Brussels. EBE actively promotes a favourable economic, business, scientific and regulatory environment for biopharmaceutical in Europe and also provides a wide range of value-added services to its 66 member companies. Membership in EBE is open to all companies using biotechnology to discover, develop and bring new medicinal products to market.

EBE – European Biopharmaceutical Enterprises
 Rue du Trône 108 | 1050 Brussels | Belgium
 Tel: +32 2 6262562 | Fax: +32 2 6262566
 info@ebe-biopharma.org | www.ebe-biopharma.org

The Biotechnologie-Industrie-Organisation Deutschland (BIO Deutschland) with offices in Berlin is the independent organisation for German biotechnology companies. The association is developing and supporting an innovative industry in Germany on the basis of modern life sciences. Founded in October 2004, BIO Deutschland currently has 200 member companies. To support its members BIO Deutschland is active on a wide range of measures like lobbying, public relations, or offering business development opportunities. BIO Deutschland is governed by a Board of Directors made up of 10 CEOs, CFOs and Managing Directors of companies that represents widely the German biotech sector.

BIO Deutschland
 Tegeler Weg 33 | berlinbiotechpark | 10589 Berlin | Germany
 Tel: +49 30 26484087 | Fax +49 30 26484088
 info@biodeutschland.org | www.biodeutschland.org

Platinum Sponsor:



Gold Sponsors:



Silver Sponsors:



Media Partner:



5-6 JUNE 2008 | MUNICH | GERMANY

Business Development Conference

Energizing Partnerships within the European Biotechnology Industry

- ▶ Select group of business development executives from international pharmaceutical corporations and European biotech companies
- ▶ Exclusive opportunities for business networking, company presentations and panel discussions on trends and strategies in biotech alliances
- ▶ Large panel of first class speakers from big pharma, successful biotechnology companies and the finance community

DAY ONE:

Thursday, 5 June, 2008

08.30–10.45 **Business breakfast & registration**

10.45–11.00 **Conference Opening Remarks**

11.00–12.30 **Session 1: Business Development Strategies**

Moderator:

Dr. Anton Gueth, Managing Director, Burrill & Company

Business Development Strategy Post-M&A: a Case Study

Anna-Lisa Picciolo-Lehrke, R & D Partnering and Business Development, Head of Oncology, UCB

Biotech – Pharma Collaborations – Keys to Successful Relationships

Jennifer D. Brenner, Head of Alliance Management, Cardiovascular and Metabolism, Novartis Pharma

Leverage In-House Disease Expertise to Build a Diversified Product Portfolio

Helmut Kessmann, CBO, Santhera Pharmaceuticals

A Perspective on Business Development Strategies

Andy Davis, Director, Business Development, Amgen Europe

12.30–14.00 **Lunch & networking**

14.00–16.00 **Company Presentations** (15 minutes each)

16.00–16.30 **Coffee break & networking**

16.30–18.00 **Panel discussion I: R&D – From Platform to Drugs**

Moderator:

Prof. Dr. Horst Domdey, Managing Director, Bio^M Biotech Cluster Development

Panelists will include:

- **Dr. Roland Kreutzer**, Managing Director, Roche Kulmbach
- **Niels Emmerich, PhD**, Managing Director and COO, Immatics Biotechnologies
- **Dr. Joerg Schneider**, Head Molecular Immunology, Transgene

18.00–19.00 **Company Presentations** (15 minutes each)

19.30–20.00 **Cocktail reception**

20.00–22.00 **Dinner**

Company Presentations:

Thursday, 5 June, 2008

14.00–16.00 · Immatics Biotechnologies
· Molmed
· Jerini
· Scil Technology
· Phenex Pharmaceuticals
· Nycomed
· Idea
· Protagen

18:00 – 19:00 · Abiogen Pharma
· Protaffin
· Ganymed Pharmaceuticals
· IMTM

Company Presentations:

Friday, 6 June, 2008

11:00 – 12:30 · Aicuris
· Caprotec Bioanalytics
· KHS Pharma Holding
· Keyneurotek
· Provitro
· Selvita

DAY TWO:

Friday, 6 June, 2008

08.00–09.00 **Welcome coffee & networking**

09.00–10.30 **Session 2: Monoclonal Antibodies and Beyond**

Moderator:

Jürg Zürcher, Partner, Ernst & Young

What Drives the Current Industry Interest for Antibody Alternatives?

Dr. Evert Küppers, CEO, Pieris

The Biogen Idec Perspective on Monoclonal Antibodies and What is Coming up Next?

Dr. Wolfgang Berthold, SVP and CTO, Biogen Idec

Partnering for Success: Antibodies and Their Fragments

Dr. Adrian Carter, Corporate Division Licensing, Boehringer Ingelheim

Mimicing the Natural Immune Response to Treat Cancer and Infections

Dr. Kirsten Drejer, CEO, Symphogen

10.30–11.00 **Coffee break & networking**

11.00–12.30 **Company Presentations** (15 min each)

12.30–13.30 **Lunch & networking**

13.30–15.00 **Panel discussion II: Is Best Management or Innovation Leadership the Key to Biotech Company Success?**

Moderator:

Mike Ward, Senior Editor, Biocentury

Panelists will include:

- **Dr. Gunther Winkler**, SVP Strategic Initiatives, Biogen Idec
- **Dr. Peter Heinrich**, CEO, Medigene
- **Dr. Simon Moroney**, CEO, Morphosys
- **Dr. Gerd Zettlmeissl**, CEO, Intercell

15.00–15.15 **Concluding Remarks**

15.15–16.30 **Networking tea time**